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Introduction
Systemic Juvenile Idiopathic Arthritis (sJIA) is a disease
with systemic inflammatory features as well as arthritis.
Before biologic agents were available, a significant
proportion of affected children suffered from poor out-
comes. The Childhood Arthritis and Rheumatology
Research Alliance (CARRA) Registry is a rich resource
of information about pediatric rheumatic diseases
including sJIA.
Objectives
We aimed to: (1) describe the characteristics of sJIA
children in the CARRA Registry; (2) identify medication
usage trends; and (3) identify subgroups at increased
risk for poor outcomes.
Methods
54 active study sites in the US and Canada contributed
528 sJIA patients from 2010-2013. Patients were enrolled
as a cross-sectional convenience sample, not an inception
cohort. Only children with a complete set of core data
were included in these analyses. We tested for subgroup
differences among binary and continuous variables across
the groups using a chi-square test or one-way analysis of
variance (ANOVA) with the null hypothesis of multiple
groups being equal.
Results
435 had a complete data set at enrollment (median age
11yrs; age of symptom onset 4.6 yrs; first visit to pediatric
rheumatologist 5.1 yrs). On the whole, disease activity
was low: 14.9% rash, 6.7% fever, median joint count 0,
and median physician global assessment 1. Significant
changes in medication usage occurred over the study
period 2010-2013: DMARD and TNF inhibitor use
decreased, while IL-6 inhibitor use increased. There were
significant differences among racial groups with African
Americans (AA) having higher mean CHAQ scores,
more poor/very poor quality of life scores and poorer
ACR functional class (p 0.0004), despite no differences in
medication use. Current and prior biologic use was more
frequent in those with longer disease duration. Children
diagnosed at a younger age (< 2 years old) had more
frequent biologic use and lower overall well being scores.
Joint damage on imaging was reported more often in
those with younger age at diagnosis (p 0.0003). 308 had
at least one follow up visit, 259 of whom had visits
occurring at least 3 mos from enrollment. Trends
towards improvement in disease activity measures were
found in these 259 patients. Of 234 children with no sys-
temic features at baseline, 91 had active arthritis (median
active joints=4). In this subset of children with persistent
arthritis, there were no differences in age at onset, time
to diagnosis or disease duration, but differences in medi-
cation use at baseline enrollment were noted (increased
current IL-6 inhibitor, corticosteroid, and NSAID use and
increased past use of all biologics).
Conclusion
This study describes characteristics and medication usage
of the largest sJIA cohort reported to date. Significant
changes occurred in sJIA medication usage from 2010-
2013, but corticosteroids are still frequently used (29.2% at
enrollment). A children have more severe disease, as
do children diagnosed at a younger age. A significant
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proportion of children have persistent arthritis despite the
use of new treatments. Further study is needed to identify
predictors of persistent arthritis in order to improve treat-
ment and outcomes in this subgroup of patients.
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